Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.
about
Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans.Antigen-induced protective and nonprotective cell-mediated immune components against Cryptococcus neoformansAb binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism.Variants of a Cryptococcus neoformans strain elicit different inflammatory responses in mice.Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle.Antibody immunity and invasive fungal infectionsVariables affecting production of monocyte chemotactic factor 1 from human leukocytes stimulated with Cryptococcus neoformans.Antibody therapy for histoplasmosis.The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response.Strain-related differences in antibody-mediated changes in gene expression are associated with differences in capsule and location of binding.Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance GroupThe capsule of the fungal pathogen Cryptococcus neoformans.The monoclonal antibody against the major diagnostic antigen of Paracoccidioides brasiliensis mediates immune protection in infected BALB/c mice challenged intratracheally with the fungus.Characterization of the antifungal functions of a WGA-Fc (IgG2a) fusion protein binding to cell wall chitin oligomers
P2860
Q33556039-D89A1BF9-4046-408F-95B4-4676BA798B69Q33754495-B8CE6678-574A-4099-8F18-A3729DABAD78Q33755308-EDB45D8D-D1FB-4041-A557-78EA855CA81AQ33997697-63939747-298A-44BC-BF84-144BFC7A5027Q35182322-98F37195-2ED9-492A-9C5B-0A25465E9132Q35447692-9584FF63-C479-4483-BC1D-3EDB03119479Q35543970-2195D558-76CF-42D2-8CD7-570B1BF0759FQ35724334-DD7AC474-D842-4916-86C7-21D4E6064D35Q35913526-AC4B4674-1E38-4B3F-9FA5-0C85BDBBE144Q36350251-6B0F2F03-5ED4-4ACC-9B2D-B7D3113FB883Q36446429-FE5D0886-7620-4F64-8506-D3A8C9A21111Q36530376-7A0CD8D1-1FC7-432E-8C28-2459ADDAF041Q37337879-9DE658F9-10A5-4DB2-A2D0-C32799FF0D48Q39757189-6904BB3C-0D87-48E1-81CD-2A14D16B478FQ41842506-338248A2-696F-4380-BDD9-15A6C73D3A89
P2860
Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.
description
1995 nî lūn-bûn
@nan
1995 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Variable efficacy of passive a ...... yptococcus neoformans strains.
@ast
Variable efficacy of passive a ...... yptococcus neoformans strains.
@en
type
label
Variable efficacy of passive a ...... yptococcus neoformans strains.
@ast
Variable efficacy of passive a ...... yptococcus neoformans strains.
@en
prefLabel
Variable efficacy of passive a ...... yptococcus neoformans strains.
@ast
Variable efficacy of passive a ...... yptococcus neoformans strains.
@en
P2093
P2860
P1476
Variable efficacy of passive a ...... yptococcus neoformans strains.
@en
P2093
A Casadevall
J Mukherjee
M D Scharff
P2860
P304
P407
P577
1995-09-01T00:00:00Z